Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 5Recurrence 3Lymphoma, Non-Hodgkin 3Lymphoma 3Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 13Rituximab 11obinutuzumab 6fludarabine phosphate 6Prednisone 6Magnetic Resonance Spectroscopy 6ibrutinib 5fludarabine 5X-Rays 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Melphalan 5Lenalidomide 5Etoposide 5Doxorubicin 5Biopsy 5tocilizumab 4Whole-Body Irradiation 4venetoclax 3polatuzumab vedotin 3glofitamab 3acalabrutinib 3Vincristine 3Mycophenolic Acid 3Leukapheresis 3Filgrastim 3Cytarabine 3Cyclosporine 3Busulfan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × glofitamab × 30 days × Clear all
NCT04077723 2026-05-29

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 1/2 Active not recruiting
498 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05169515 2026-05-18

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1 Recruiting
121 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡